Cardiology - Case Reports Open access

Dilated cardiomyopathy - guidelines for personalization of care

Authors

Published
1 April 2025
Section
Cardiology - Case Reports

Abstract

The term “dilated cardiomyopathy” (DCM) refers to a family of diseases characterized by complex interactions between environment and genetic predisposition. Diagnostic tools such as cardiac magnetic resonance imaging should be systematically implemented in clinical practice to define the etiological cause and undertake a specific treatment. We present the case of a young man with DCM and severe left ventricular dysfunction. The patient has a family history of sudden cardiac death (SCD). He is affected by a psychiatric pathology and has a history of alcohol and drug addiction. Many diagnostic hypotheses have been considered for etiological research. The use of a wearable defibrillator to temporarily protect the patient from SCD risk pending the completion of the diagnostic path to establish DCM etiology and the implementation of optimal medical therapy was considered. However, because of the underlying psychiatric pathology and the possibility of poor adherence to the maintenance of the wearable device, the patients would not have been sufficiently protected. Due to the young age of the patient, it was decided to make a personalized therapeutic choice, and he underwent implantation of a subcutaneous defibrillator.

References

  1. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023;44:3503-626. DOI: https://doi.org/10.1093/eurheartj/ehad194
  2. Lei Z, Cao J, Wu J, Lu Y, et al. Identification of the communal pathogenesis and immune landscape between viral myocarditis and dilated cardiomyopathy. ESC Heart Fail 2024;11:282-92. DOI: https://doi.org/10.1002/ehf2.14585
  3. Orphanou N, Papatheodorou E, Anastasakis A. Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments. Heart Fail Rev 2022;27:1173-91. DOI: https://doi.org/10.1007/s10741-021-10139-0
  4. Merlo M, Cannatà A, Gobbo M, et al. Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail 2018;20:228-39. DOI: https://doi.org/10.1002/ejhf.1103
  5. William Bracamonte-Baran, Daniela Čiháková. Cardiac autoimmunity: myocarditis. Adv Exp Med 2017;1003:187-221. DOI: https://doi.org/10.1007/978-3-319-57613-8_10
  6. Ekström K, Lehtonen J, Kandolin R, et al. Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail 2016;18:1452-8. DOI: https://doi.org/10.1002/ejhf.606
  7. D'Ambrosio A, Patti G, Manzoli A, et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001;85:499-504. DOI: https://doi.org/10.1136/hrt.85.5.499
  8. Yamada T, Nomura S. Recent findings related to cardiomyopathy and genetics. Int J Mol Sci 2021;22:12522. DOI: https://doi.org/10.3390/ijms222212522
  9. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 2007;28:3076-93. DOI: https://doi.org/10.1093/eurheartj/ehm456
  10. Könemann H, Dagres N, Merino JL, et al. Spotlight on the 2022 ESC guideline management of ventricular arrhythmias and prevention of sudden cardiac death: 10 novel key aspects. Europace 2023;25:euad091. DOI: https://doi.org/10.1093/europace/euad091
  11. Fernández-Solà J. The effects of ethanol on the heart: alcoholic cardiomyopathy. Nutrients 2020;22:572. DOI: https://doi.org/10.3390/nu12020572
  12. Domínguez F, Adler E, García-Pavía P. Alcoholic cardiomyopathy: an update. Eur Heart J 2024;45:2294-305. DOI: https://doi.org/10.1093/eurheartj/ehae362
  13. Torres-Acosta N, O'Keefe JH, O'Keefe CL, Lavie CJ. Cardiovascular effects of ADHD therapies: JACC review topic of the week. J Am Coll Cardiol 2020;76:858-66. DOI: https://doi.org/10.1016/j.jacc.2020.05.081
  14. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43:3997-4126. DOI: https://doi.org/10.1093/eurheartj/ehac699
  15. Casolo G, Gulizia MM, Aschieri D, et al. Position paper ANMCO: guida all’uso appropriato del defibrillatore indossabile nella pratica clinica per i pazienti ad elevato rischio transitorio di morte improvvisa. G Ital Cardiol 2023;24:394-411. [Article in Italian]. DOI: https://doi.org/10.1714/4026.40015
  16. Mc Donagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-726. DOI: https://doi.org/10.1093/eurheartj/ehab368
  17. Boriani G, Vitolo M, Leyva F. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: what are the barriers to implementation in the 'real world'? Eur J Heart Fail 2022;24:1223-6. DOI: https://doi.org/10.1002/ejhf.2581
  18. Probst V, Boveda S, Sadoul N et al. Subcutaneous implantable cardioverter defibrillator indication in prevention of sudden cardiac death in difficult clinical situations: a French expert position paper. Arch Cardiovasc Dis 2020;113:359-66. DOI: https://doi.org/10.1016/j.acvd.2020.03.011
  19. Migliore F, Mattesi G, Zorzi A, et al. Il defibrillatore sottocutaneo nella pratica clinica G Ital Cardiol 2019;20:641-50. [Article in Italian]. DOI: https://doi.org/10.1714/3254.32225
  20. Holtstiege V, Meier C, Bietenbeck M, et al. Clinical experience regarding safety and diagnostic value of cardiovascular magnetic resonance in patients with a subcutaneous implanted cardioverter/defibrillator (S-ICD) at 1.5 T. J Cardiovasc Magn Reson 2020;22:35. DOI: https://doi.org/10.1186/s12968-020-00626-y

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.